Shopping Cart
- Remove All
- Your shopping cart is currently empty
JC-171, a selective inhibitor of the NLRP3 inflammasome, effectively inhibits LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages with an IC50 of 8.45 μM[1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $297 | 7-10 days | |
1 mL x 10 mM (in DMSO) | $296 | 7-10 days |
Description | JC-171, a selective inhibitor of the NLRP3 inflammasome, effectively inhibits LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages with an IC50 of 8.45 μM[1]. |
In vitro | JC-171 (0-100 μM) inhibits NLRP3 inflammasome activation and IL-1β production in primary macrophages in a dose-dependent manner, with cell viability assessed using J774A.1 murine macrophage cells[1]. |
In vivo | JC-171 treatment delays progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE) in mice[1]. Animal Model: Mice immunized subcutaneously with 200 μg Myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide emulsified in Complete Freund's Adjuvant (CFA) on day 0, followed by injection of 200 ng of pertussis toxin. |
Molecular Weight | 384.83 |
Formula | C16H17ClN2O5S |
Cas No. | 2112809-98-8 |
Relative Density. | 1.401 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 250 mg/mL (649.64 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.